azacitidine has been researched along with Agnogenic Myeloid Metaplasia in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Gardner, J; Heenan, J; Hitchins, S; Mohamed, M; Shahidi, R; Sharma, A | 1 |
| Diamantopoulos, PT; Giannakopoulou, N; Hatzidavid, S; Viniou, NA | 1 |
| Andermann, TM; Batzoglou, S; Bhatt, AS; Bishara, A; Culver, RN; Handy, C; Ji, HP; Kang, JB; Moss, EL; Tkachenko, E; Weng, Z; Wood, C; Zlitni, S | 1 |
| Hiroshima, Y; Kazumoto, H; Kirihara, T; Kitahara, M; Kobayashi, H; Sato, K; Shishido, T; Sumi, M; Ueki, T; Uematsu, N | 1 |
| Aiba, K; Dobashi, N; Fukushima, R; Ishii, H; Ito, Y; Machishima, T; Ohba, R; Shiota, Y; Usui, N; Yahagi, Y; Yamauchi, H; Yano, S; Yokoyama, H | 1 |
| Basak, G; Boguradzki, P; Chmarzyńska-Mróz, E; Drozd-Sokołowska, J; Dwilewicz-Trojaczek, J; Jędrzejczak, W; Karakulska-Prystupiuk, E; Kulikowska, A; Paluszewska, M; Stefaniak, A; Waszczuk-Gajda, A | 1 |
| Cairoli, R; Cassin, R; Cortelezzi, A; Fattizzo, B; Freyrie, A; Giannarelli, D; Molteni, A; Pennisi, M; Reda, G; Riva, M | 1 |
| Anaclerico, B; Andriani, A; Aroldi, A; Breccia, M; Carmosino, I; Centra, A; Di Veroli, A; Elli, E; Fianchi, L; Foà, R; Latagliata, R; Martini, V; Montanaro, G; Montanaro, M; Niscola, P; Trapè, G; Villivà, N; Voso, MT | 1 |
| Billings, S; Englehaupt, R; Hasrouni, E; Kalaycio, M; Liu, Y; Rogers, HJ; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Cinalli, T; Colaluca, K; Duong, HK; Rogers, HJ; Saunthararajah, Y; Sekeres, MA; Stein, BL; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Mascarenhas, J | 1 |
| Badar, T; Borthakur, G; Cortes, JE; Daver, N; Jabbour, E; Kantarjian, HM; Newberry, KJ; Pemmaraju, N; Pierce, SR; Ravandi, F; Verstovsek, S | 1 |
| Hussein, K; Lasho, T; Mesa, RA; Pardanani, A; Rivera, C; Tefferi, A; Verstovsek, S; Wu, W | 1 |
| Danilov, AV; Feeney, DM; Miller, KB; Relias, V | 1 |
| Hemavathy, K; Wang, JC | 1 |
| Hoffman, R; Ishii, T; Sozer, S; Wang, J; Wang, X; Xu, M; Zhang, W | 1 |
| Blagitko-Dorfs, N; Daskalakis, M; Hackanson, B | 1 |
| Hoffman, R; Li, Y; Lu, M; Najfeld, V; Tripodi, J; Wang, X; Xu, M; Zhang, W | 1 |
| Bhagat, TD; Bhattacharyya, S; Christopeit, M; Greally, JM; Maciejewski, JP; McDevitt, M; Melnick, AM; Mo, Y; Moliterno, A; Nischal, S; Pardanani, A; Sohal, D; Steidl, U; Suzuki, M; Verma, A; Will, B; Yu, Y; Zhou, L | 1 |
| Odenike, O; Tefferi, A | 1 |
| Bruno, E; Hoffman, R; Hu, W; Ishii, T; Lindgren, V; Shi, J; Sozer, S; Xu, M; Zhang, W; Zhao, Y | 1 |
| Cortes, JE; Garcia-Manero, G; Kantarjian, H; Kornblau, S; Manshouri, T; Quintás-Cardama, A; Ravandi, F; Thomas, D; Tong, W; Verstovsek, S | 1 |
6 review(s) available for azacitidine and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Myelodysplastic syndrome with myelofibrosis in which azacitidine therapy was effective and cord blood transplantation was carried out.
Topics: Azacitidine; Cord Blood Stem Cell Transplantation; Fetal Blood; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; Transplantation, Homologous | 2017 |
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; Retrospective Studies; Treatment Outcome | 2018 |
Rationale for combination therapy in myelofibrosis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biphenyl Compounds; Clinical Trials as Topic; Decitabine; Drug Therapy, Combination; Gene Expression; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Hydroxamic Acids; Indoles; Janus Kinase 2; Mutation; Nitriles; Panobinostat; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Recombinant Proteins; Serum Amyloid P-Component | 2014 |
Epigenetic modifications: new therapeutic targets in primary myelofibrosis.
Topics: Acetylation; Animals; Azacitidine; Cell Proliferation; Decitabine; DNA Methylation; Gene Silencing; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Immune System; Primary Myelofibrosis | 2009 |
Decitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Stem Cell Transplantation; Transplantation, Homologous | 2010 |
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins | 2005 |
2 trial(s) available for azacitidine and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
5-Azacitidine has limited therapeutic activity in myelofibrosis.
Topics: Aged; Azacitidine; Female; Humans; Male; Middle Aged; Primary Myelofibrosis; Treatment Failure; Treatment Outcome | 2009 |
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; DNA Methylation; Female; Humans; Janus Kinase 2; Male; Middle Aged; Neutropenia; Polycythemia Vera; Primary Myelofibrosis; Thrombocythemia, Essential; Treatment Outcome | 2008 |
14 other study(ies) available for azacitidine and Agnogenic Myeloid Metaplasia
| Article | Year |
|---|---|
Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Fibrosis; Humans; Myelodysplastic Syndromes; Primary Myelofibrosis; Prospective Studies; Retrospective Studies; Treatment Outcome | 2022 |
Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Strain-resolved microbiome sequencing reveals mobile elements that drive bacterial competition on a clinical timescale.
Topics: Anti-Infective Agents; Azacitidine; Azithromycin; Bacteria; Ciprofloxacin; Diet; DNA, Bacterial; Feces; Gastrointestinal Microbiome; Genome, Bacterial; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Metagenome; Middle Aged; Myelodysplastic Syndromes; Primary Myelofibrosis; RNA-Seq; Sequence Analysis, DNA | 2020 |
Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cord Blood Stem Cell Transplantation; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Recurrence; Salvage Therapy; Transplantation, Homologous; Treatment Outcome | 2020 |
Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Neoplasms; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplasm, Residual; Primary Myelofibrosis; Retrospective Studies; Transplantation, Homologous; Young Adult | 2018 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Melphalan; Middle Aged; Mutation; Myeloproliferative Disorders; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Remission Induction; Retrospective Studies; Thrombocythemia, Essential; Treatment Outcome | 2019 |
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Male; Middle Aged; Primary Myelofibrosis; Risk Factors; Sweet Syndrome; Treatment Outcome | 2014 |
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Modification Methylases; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Primary Myelofibrosis; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 2015 |
Decitabine is an effective treatment of idiopathic myelofibrosis.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Modification Methylases; Humans; Male; Primary Myelofibrosis; Treatment Outcome | 2009 |
Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.
Topics: Animals; Antigens, CD34; Azacitidine; Bone Marrow; Chromatin; Decitabine; Down-Regulation; Humans; Hydroxamic Acids; Mice; Mice, Inbred NOD; Mice, SCID; Primary Myelofibrosis; Receptors, CXCR4; Spleen | 2009 |
Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Bone Marrow; Cells, Cultured; Chromatin; Decitabine; Hematopoietic Stem Cells; Humans; Hydroxamic Acids; Immunoblotting; Interleukin Receptor Common gamma Subunit; Janus Kinase 2; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; Primary Myelofibrosis; Protein Synthesis Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vorinostat | 2010 |
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Line, Tumor; Decitabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Female; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Polycythemia Vera; Primary Myelofibrosis; Proto-Oncogene Proteins; Repressor Proteins; Thrombocythemia, Essential | 2013 |
Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.
Topics: Antigens, CD34; Antimetabolites, Antineoplastic; Azacitidine; Cell Movement; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hematopoietic Stem Cells; Homozygote; Humans; Hydroxamic Acids; Mutation; Primary Myelofibrosis; Protein Synthesis Inhibitors; Receptors, CXCR4; Stem Cells | 2007 |